Department of Family Medicine and Rural Health, Faculty of Health Sciences, Walter Sisulu University, Cecilia Makiwane Hospital, East London Hospital Complex, East London, South Africa.
School of Science and Technology, Sefako Makgatho Health Sciences University, Ga-Rankuwa, Pretoria, South Africa.
Clin Infect Dis. 2021 Nov 16;73(10):1750-1758. doi: 10.1093/cid/ciab206.
This study describes the characteristics of pregnant women on antiretroviral therapy (ART) and the rate of peripartum virologic suppression in a large prevention of mother-to-child transmission cohort who delivered in some selected maternity centers in Eastern Cape Province, South Africa. In addition, the study examines the factors associated with virologic suppression in the cohort.
This multicenter, retrospective cross-sectional analysis included medical data of 1709 women with human immunodeficiency virus between September 2015 and May 2016 in Eastern Cape Province. The main outcome measure was the rate of peripartum virologic suppression, defined as viral load (VL) <1000 copies/mL and undetectable viremia (VL <20 copies/mL). Correlates of peripartum virologic suppression and undetectable viremia were examined by fitting logistic regression model analysis.
Of 1463 women with available VL results, the overall rate of peripartum suppression was 82%, and undetectable viremia was 56.9%. Being aged 24 years or younger (adjusted odds ratio [AOR], 0.68 [95% confidence interval {CI}, .48-.94]), smoking during pregnancy (AOR, 0.50 [95% CI, .28-.90]), and starting ART in the first trimester were associated with lower odds of viral suppression (<1000 copies/mL). Women who had never defaulted ART had an increased odds of having an undetectable VL (AOR, 3.09 [95% CI, 2.12-4.49]) and virologic suppression (AOR, 3.88 [95% CI, 2.62-5.74]) compared to those who defaulted.
More than half of the women achieved undetectable VL, and 4 in 5 women achieved viral suppression at delivery in the region. Early antenatal booking, combined with enhanced adherence support for pregnant women on ART, would be crucial toward achieving the goal of elimination of mother-to-child transmission in the region.
本研究描述了在南非东开普省一些选定的妇产中心接受抗逆转录病毒疗法 (ART) 的孕妇的特征,以及围产期病毒学抑制率。此外,本研究还探讨了队列中与病毒学抑制相关的因素。
这是一项多中心、回顾性的横断面分析,纳入了 2015 年 9 月至 2016 年 5 月东开普省 1709 名艾滋病毒感染者的医疗数据。主要结局指标是围产期病毒学抑制率,定义为病毒载量(VL)<1000 拷贝/ml 和不可检测的病毒血症(VL<20 拷贝/ml)。通过拟合逻辑回归模型分析,检查围产期病毒学抑制和不可检测病毒血症的相关因素。
在 1463 名有可用 VL 结果的女性中,总体围产期抑制率为 82%,不可检测病毒血症率为 56.9%。年龄在 24 岁或以下(调整后的优势比 [AOR],0.68 [95%置信区间 {CI},0.48-0.94])、怀孕期间吸烟(AOR,0.50 [95% CI,0.28-0.90])和在孕早期开始接受 ART 治疗与较低的病毒抑制率相关(<1000 拷贝/ml)。从未中断 ART 治疗的女性与具有不可检测 VL(AOR,3.09 [95% CI,2.12-4.49])和病毒学抑制(AOR,3.88 [95% CI,2.62-5.74])的几率更高。
该地区超过一半的女性达到了不可检测的 VL,五分之四的女性在分娩时达到了病毒抑制。早期产前预约,结合对接受 ART 的孕妇进行强化依从性支持,对于实现该地区消除母婴传播的目标至关重要。